Comparison of the cutaneous iontophoretic delivery of rasagiline and selegiline across porcine and human skin in vitro.

[1]  P. LeWitt.  MAO-B inhibitor know-how , 2009, Neurology.

[2]  L. Elmer,et al.  The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy , 2008 .

[3]  M. Steiger.  Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease , 2007, European journal of neurology.

[4]  K. Dashtipour,et al.  Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. , 2007, Clinical therapeutics.

[5]  A. Patkar,et al.  Selegiline transdermal system: Current awareness and promise , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[6]  J. Subramony,et al.  Microprocessor controlled transdermal drug delivery. , 2006, International journal of pharmaceutics.

[7]  R. Howland.  Transdermal selegiline: a novel MAOI formulation for depression. , 2006, Journal of psychosocial nursing and mental health services.

[8]  P. Masand,et al.  Transdermal Selegiline: The New Generation of Monoamine Oxidase Inhibitors , 2006, CNS Spectrums.

[9]  P. Jenner.  Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson’s disease , 2004, Neurology.

[10]  M. Youdim,et al.  Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline , 2004, Neuroscience Letters.

[11]  A. Azzaro,et al.  Daily transdermal administration of selegiline to guinea‐pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues , 2003, The Journal of pharmacy and pharmacology.

[12]  J. Amsterdam,et al.  Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. , 2002, The American journal of psychiatry.

[13]  Y. Kalia,et al.  Electrorepulsion Versus Electroosmosis: Effect of pH on the lontophoretic Flux of 5-Fluorouracil , 1999, Pharmaceutical Research.

[14]  J. Barrett,et al.  Bioequivalence of Selegiline HCL: Guidance for a “Highly Variable” Drug , 1996 .

[15]  J. C. Keister,et al.  Application of electrodiffusion theory for a homogeneous membrane to iontophoretic transport through skin , 1989 .

[16]  M. Francoeur,et al.  Enhanced percutaneous absorption via iontophoresis. I: Evaluation of an in vitro system and transport of model compounds , 1986 .

[17]  P. Lazarovici,et al.  Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease? , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.

[18]  K. Tipton,et al.  Estimation of monoamine oxidase concentrations in soluble and membrane-bound preparations by inhibitor binding. , 1994, Journal of neural transmission. Supplementum.

[19]  J. Sweeney,et al.  A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor. , 1989, Archives of general psychiatry.